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Abstract
 
We describe here a previously unrecognized property of dendritic cells (DCs), the ability to
deacylate the lipid A moiety of gram-negative bacterial LPSs. Both immature DCs of the XS52
cell line and bone marrow–derived DCs produce acyloxyacyl hydrolase, an enzyme that detoxi-
fies LPS by selectively removing the secondary acyl chains from lipid A. Acyloxyacyl hydrolase
expression decreased when DCs were incubated with IL-4, IL-1
 
 
 
, TNF
 
 
 
, and an agonistic
CD40 antibody (maturation cocktail), and increased after treatment with LPS, CpG oligodeoxy-
nucleotides, or a gram-positive bacterium (
 
Micococcus luteus
 
). Maturation cocktail treatment also
diminished, whereas LPS treatment enhanced or maintained the cells’ ability to kill 
 
Escherichia coli
 
,
deacylate LPS, and degrade bacterial protein. Enzymatic deacylation of LPS is an intrinsic, regu-
lated mechanism by which DCs may modulate host responses to this potent bacterial agonist.
Key words: lipopolysaccharide • dendritic cell • acyoxyacyl hydrolase • gram-negative bacteria • 
deacylation
 
Introduction
 
Dendritic cells (DCs),
 
*
 
 the most potent antigen-presenting
cells, initiate and modulate both innate and adaptive im-
mune responses. Immature DCs reside in nonlymphoid
tissues, such as the skin, where they are poised to capture
and process microbial invaders. After an encounter with
bacteria or bacterial components, immature DCs migrate
via lymphatic channels to the T cell areas of regional lymph
nodes, where they mature, losing their antigen-capturing
and -processing ability and becoming specialized for pre-
senting antigens to T cells (1–3). DC maturation can be
induced in vitro and in vivo by various stimuli, such as in-
flammatory cytokines (TNF
 
 
 
 and IL-1
 
 
 
), CD40 ligand,
and several conserved microbial molecules (LPS, peptidogly-
cans, bacterial lipoproteins, DNA that contains unmeth-
ylated CpG motifs, and viral double-stranded RNA; refer-
ences 2, 4). Different agonists may drive distinct maturation
events and act synergistically to induce the maturation of
DCs (5–7).
In addition to inducing adaptive immune responses to
microbial antigens, DCs also contribute to innate immunity
by ingesting and killing microbes and by secreting media-
tors that recruit macrophages, natural killer cells, and eosin-
ophils to sites of infection (2, 4). However, little is known
about how immature DCs help control bacterial infection
and/or prevent harmful host responses to bacteria or bacte-
rial components. In the studies described here, we show
that these cells are able to degrade the most potent agonist
contained in the gram-negative bacterial cell wall, the lipid
A moiety of LPS.
Lipid A, the conserved bioactive center of LPS, has a
glucosamine disaccharide backbone. In enterobacterial lipid
A, four molecules of 3-hydroxytetradecanoate (3-OH-14:0)
attach directly to this backbone. The hydroxyl groups of
two or three of the 3-OH-14:0 residues are substituted
with secondary acyl chains (laurate and myristate) to form
acyloxyacyl groups (Fig. 1 A). Animals have an enzyme,
acyloxyacyl hydrolase (AOAH), that removes secondary
fatty acyl chains from the lipid A regions of diverse LPSs
and greatly reduces the molecules’ ability to elicit toxic re-
sponses in vivo (8). Moreover, in vitro studies using human
monocytes, endothelial cells, and neutrophils have shown
that the partially deacylated LPS produced by AOAH can
be an LPS antagonist (9–11). Mice that are unable to pro-
duce AOAH due to targeted gene disruption have exagger-
ated antibody responses to LPS (unpublished results).
Although AOAH had been detected previously only in
neutrophils and monocyte macrophages, we found that im-
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 AOAH, acyloxyacyl hydrolase; BMDC,
bone marrow–derived DC; cRPMI, complete RPMI; DC, dendritic cell;
ODN, oligodeoxynucleotide; TLR, toll-like receptor.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
1746
 
Dendritic Cells Deacylate Bacterial Lipopolysaccharide
 
mature DCs also produce the enzyme. We studied the abil-
ity of DCs to alter their expression of AOAH, and their
ability to deacylate LPS in ingested 
 
Escherichia coli
 
 in re-
sponse to host (inflammatory cytokines and CD40 ligand)
or bacterial (LPS, 
 
E. coli, Micrococcus luteus
 
 [peptidoglycan],
and CpG oligonucleotides) stimuli. The results indicate
that DCs coordinate AOAH expression and LPS deacyla-
tion with many other antibacterial responses, increasing or
decreasing their ability to process this important bacterial
molecule in response to environmental cues.
 
Materials and Methods
 
Materials. 
 
Unless otherwise indicated, reagents were ob-
tained from Sigma-Aldrich. Phosphorothioate-modified CpG
(5
 
 
 
-TCCATGACGTTCCTGATGCT-3
 
 
 
) and GpC (5
 
 
 
-TCC-
ATGAGCTTCCTGATGCT-3
 
 
 
) oligodeoxynucleotides (ODNs)
were obtained from Invitrogen.
 
AOAH
 
   
 
 Mice. 
 
Targeted disruption of the murine AOAH
gene was accomplished in embryonic stem cells from 129S6/
SvEvTac mice by inserting a neomycin resistance gene in the first
AOAH exon, and by eliminating a 705-bp region that encodes
untranslated mRNA, the translation start site, the leader and pro-
peptide sequences, and 41 amino acids of the small subunit of the
enzyme (12). Mouse DNA was screened by Southern blot analy-
sis using an EcoRI–BamHI probe derived from the 5
 
 
 
 genomic
sequence upstream of the long arm of the targeting vector. For
the experiments described here, peritoneal macrophages and
bone marrow–derived DCs (BMDCs) were isolated from AOAH
knockout and wild-type 129S6/SvEvTac mice.
 
Cell Lines. 
 
XS52 is an immature DC line derived from new-
born BALB/c mouse epidermis (13). XS52 cells were maintained
in XS medium (complete RPMI [cRPMI] supplemented with
0.5 ng/ml recombinant murine GM-CSF [rmGM-CSF; R&D
Systems] and culture supernatant [5%, vol/vol] from a NS47 stro-
mal cell line. cRPMI is RPMI 1640 (Cellgro) with 10% heat-
inactivated FBS (endotoxin 
 
  
 
0.06 EU/ml; Hyclone), 2 mM
 
l
 
-glutamine (GIBCO BRL), 100 
 
 
 
M of nonessential amino acids
(GIBCO BRL), 100 U/ml penicillin, 0.1 mg/ml streptomycin
(GIBCO BRL), 10 
 
 
 
M of sodium pyruvate, 25 mM Hepes, pH
7.4, and 50 
 
 
 
M 2-mercaptoethanol. NS47 cells (13) were cul-
tured in cRPMI medium. XS106, a mature DC line established
from A/J mice (14), was also cultured in XS medium. The
BALB/c-derived macrophage line RAW264.7 was maintained in
DMEM (Cellgro) supplemented with 10% heat-inactivated FBS,
2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and 0.1 mg/ml strepto-
mycin. Murine macrophage cell lines P388D1 and J774 were
cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated FBS, 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, and
0.1 mg/ml streptomycin.
 
BMDCs and Peritoneal Macrophages. 
 
DCs were generated
from bone marrow as described by Inaba et al. (15) with minor
modifications. Marrow was flushed out of the femurs and tibias.
Red blood cells were lysed using RBC lysing buffer and cells
were cultured in 6-well plates at 6 
 
 
 
 10
 
6
 
 cells per well in 3 ml
cRPMI medium supplemented with 10 ng/ml rmGM-CSF. On
day 3 of culture, nonadherent cells were removed, and 4 ml of
fresh medium containing rmGM-CSF were added. On day 7,
nonadherent CD11c
 
 
 
 cells were purified using anti-CD11c
monoclonal antibody N418 coupled to magnetic microbeads
(Miltenyi Biotec). Fc receptors were blocked with 0.5 mg/ml of
normal mouse IgG (Caltag Laboratories) before the cells were in-
cubated with the beads. Flow cytometric analysis (FACScan™;
Becton Dickinson) showed that 
 
 
 
95% of the sorted cells were
CD11c
 
 
 
. These purified CD11c
 
 
 
 cells had DC morphology
(veiled and dendritic processes) when viewed using light micros-
copy. Thioglycollate-elicited peritoneal macrophages were pre-
pared as described previously (16). All cells were maintained at
37
 
 
 
C in a humidified atmosphere of 5% CO
 
2
 
 and air.
 
Induction of DC Differentiation. 
 
We followed the method of
Yamada and Katz (17). In brief, XS52 cells were cultured in
cRPMI medium supplemented with rmGM-CSF and IL-4 (10
ng/ml each) for 6 d; the medium was replaced with fresh me-
dium containing rmGM-CSF and IL-4 on day 3. The cells were
cultured for three additional days in the presence of GM-CSF,
IL-4, TNF-
 
 
 
 (10 ng/ml each, all from R&D Systems), 10 ng/ml
IL-1
 
 
 
 (BD Biosciences), and 4 
 
 
 
g/ml anti-CD40 (clone 1C40;
R&D Systems). To study the impact of LPS on XS52 cell matu-
ration, 10 ng/ml of 
 
E. coli
 
 O9 LPS (purified using hot phenol-
water extraction from 
 
E. coli
 
) was added to the cells in XS me-
dium. Cells were either harvested at 24 h or they were incubated
for 9 d; the medium was replaced with fresh XS52 medium con-
taining 10 ng/ml LPS on days 3 and 6. To study the impact of
living 
 
E. coli
 
 on DC maturation, 10
 
5
 
 CFU/ml of an overnight
culture of 
 
E. coli
 
 O9 was added to XS52 cells (bacteria/cell ratio 
 
 
 
1:5) in XS medium without antibiotics and incubated at 37
 
 
 
C for
1 h. The cells were washed with cRPMI medium without antibi-
otics, cultured in XS medium that contained 50 
 
 
 
g/ml gentami-
cin, and were harvested at 24 h. When incubation was continued
for 9 d, this procedure was repeated on days 3 and 6, and the cells
were harvested on day 9.
To induce the maturation of BMDCs, 10 ng/ml LPS, 1 
 
 
 
M
CpG ODN, and control GpC ODN, 40 
 
 
 
g/ml 
 
M. luteus
 
 or a
cocktail of IL-4, TNF
 
 
 
, IL-1
 
 
 
, and agonistic anti-CD40 anti-
body were added to day 5 BMDC cultures. On day 7, the non-
adherent cells were harvested, and CD11c
 
 
 
 cells were sorted by
CD11c monoclonal antibody–conjugated magnetic microbeads.
 
Deacylation of Purified LPS. 
 
Double-labeled LPS (
 
14
 
C-glu-
cosamine backbone and 
 
3
 
H-fatty acyl chains; reference 18) was
incubated with cell lysates for 16 h at 37
 
 
 
C in AOAH reaction
mixture (1 mg/ml of fatty acid–free bovine serum albumin,
5 mM CaCl
 
2
 
, 0.05% Triton X-100, and 20 mM Tris-citrate, pH
5). The reaction was terminated by adding 2.5 volumes of 100%
ethanol. After centrifugation to precipitate intact LPS and par-
tially deacylated LPS, the 
 
3
 
H-fatty acids in the supernatant were
quantitated by 
 
 
 
-scintillation counting (Packard Instrument Co.).
Confirmation that the deacylating activity was AOAH-like (re-
leasing only 12:0 and 14:0 from the LPS) was obtained using
TLC (19).
 
Deacylation of LPS in E. coli. E
 
. 
 
coli
 
 LCD25 is unable to pro-
duce its own acetate or use acetate as carbon or energy source
(20). When LCD25 cells are cultured in minimal medium with
sodium 2-[
 
14
 
C]acetate (NEN Life Science Products), 
 
14
 
C is ex-
clusively incorporated into fatty acyl chains. The method of Katz
et al. (21) was followed to 
 
14
 
C-label fatty acyl chains in LCD25,
yielding 
 
 
 
20,000 dpm /10
 
6
 
 CFU. 
 
14
 
C-Labeled LCD25 bacteria
were added to XS52 cells (cell/bacteria ratio 
 
 
 
 1:50) in XS me-
dium without antibiotics and incubated for 1 h at 37
 
 
 
C. The cells
were washed and incubated for 6 or 24 h in XS medium with 50
 
 
 
g/ml gentamicin to kill extracellular bacteria. For BMDCs,
nonadherent cells were harvested on day 7 of culture, mixed with
 
14
 
C-labeled LCD25 (cell/bacteria ratio 
 
 
 
 1:50) in cRPMI
medium without antibiotics, and incubated at 37
 
 
 
C for 1 h.
The CD11c
 
 
 
 cells were purified by magnetic microbeads and the
CD11c
 
 
 
 cells and unbound bacteria were washed away. TheT
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sorted CD11c
 
 
 
 cells were cultured in cRPMI supplemented with
10 ng/ml rmGM-CSF and 50 
 
 
 
g/ml gentamicin for 6 or 24 h.
The cells and culture media were pooled to measure LPS deacyl-
ation. At the 0-h time point, samples were harvested immediately
after 
 
14
 
C-labeled LCD25 bacteria were added to DCs.
LPS deacylation was quantitated by calculating the loss of the
fatty acyl chains from LPS (21). In brief, the interphase of a
Bligh-Dyer extraction (22), which contains LPS and partially
deacylated LPS, was washed three times with chloroform and
dried under argon. The interphase was hydrolyzed with 4 M HCl
and 4 M NaOH (16). The hydrolyzed interphase was extracted
again and the chloroform phase, which contains released fatty ac-
ids, was recovered, dried, and resuspended in 100 
 
 
 
l methanol/
chloroform 1:1 (vol/vol). The interphase-derived fatty acids were
resolved by TLC. First, the primary (3-OH-14:0) and secondary
(12:0 and 14:0) fatty acids were separated using TLC system 1
(silica gel G, petroleum ether/diethyl ether/acetic acid 
 
  
 
70:30:
1). The two bands containing 3-OH-14:0 and the nonhydroxyl-
ated fatty acids were visualized by phosphorimager (Molecular
Dynamics). The 3-OH-14:0 band was scraped and the radioac-
tivity was quantitated by 
 
 
 
-scintillation counting. The nonhy-
droxylated fatty acids were extracted from the silica gel and re-
solved on a reverse-phase KC18 plate, using acetic acid/
acetonitrile (3:7) as the solvent (TLC, system 2); the plates were
developed, dried, and developed again to get a better separation
of fatty acids. The bands corresponding to each species of nonhy-
droxylated fatty acid (12:0, 14:0, and 16:0) were scraped and
quantitated. The disintegrations per minute recovered from each
band were normalized to the total disintegrations per minute
measured for each sample before extraction. The values at t 
 
  
 
0 h
were set as 100%, and the values at other time points were con-
verted to percentages by comparing them to the t 
 
  
 
0–h value.
For example, 12:0 attached to LPS at 24 h (%) 
 
 
 
 (12:0 recovered
at 24 h/total dpm of 24-h sample before extraction)/(12:0 recov-
ered at 0 h/total dpm of 0-h sample before extraction) 
 
 
 
 100.
The distribution of the radioactivity in each sample was assayed
in duplicate.
At the end of the maturation experiment, there were more
cells in the cytokine-treated wells, and fewer in the LPS-treated
wells, than in the untreated wells. The cell mass was estimated by
measuring the amount of cell protein in each well.
 
Bacterial Protein Degradation. 
 
To label bacterial proteins,
LCD25 cells were cultured in minimal medium plus 1 mM so-
dium acetate with 0.04 
 
 
 
M 
 
3
 
H-arginine (NEN Life Science
Products) and 10 
 
 
 
M of nonradiolabeled 
 
l
 
-arginine, yielding
 
 
 
3,500 
 
3
 
H dpm/10
 
6
 
 bacterial CFUs. 
 
3
 
H-Arginine–labeled
LCD25 were added to XS52 cells (cell/bacteria ratio 
 
 
 
 1:50). In-
cubation, washing, and harvesting were performed as in the LPS
deacylation protocol described in previous paragraphs. The 0-h
time point samples were harvested immediately after the 
 
3
 
H-argi-
nine–labeled LCD25 bacteria were added to DCs. 0.5 ml of each
sample was mixed with an equal volume of 20% TCA, incubated
at 4
 
 
 
C for 20 min, and centrifuged. The radioactivities in the su-
pernatant and pellet were counted. The fraction of the counts
that was TCA-insoluble at 0 h was considered to represent 100%,
and the values at later time points were converted to percentages
by comparing them to the t 
 
  
 
0–h value. Each experimental
condition was assayed in duplicate.
 
Flow Cytometry. 
 
XS52 cells were washed with PBS and har-
vested with PBS containing 2 mM EDTA. BMDCs were puri-
fied by magnetic cell sorting. After blocking Fc binding with 0.5
mg/ml of normal mouse IgG, cells were incubated with anti–
CD14-PE (rmC5–3), anti–CD40-PE (3:23), anti–CD86-PE
 
(GL1), anti–CD11c-FITC (HL3), and corresponding isotype
controls. These antibodies were all purchased from BD Bio-
sciences and used at 5 
 
 
 
g/ml. The samples were analyzed by
FACScan
 
™
 
, gating on cells that excluded propidium iodide. Data
were analyzed using CELLQuest
 
™
 
 (Becton Dickinson) software.
 
Phagocytosis. 
 
10
 
6
 
 DCs were washed with PBS and suspended
in 0.2 ml cRPMI medium. 0.05 ml of 10
 
9
 
 bacteria/ml Bodipy–
 
E. coli
 
 (Molecular Probes) was added to the cells, which were in-
cubated at 37
 
 
 
C in the dark for 1 h before they were chilled on
ice to stop phagocytosis. To quench extracellular fluorescence,
0.25 ml of 0.2% trypan blue in PBS was added before analysis by
flow cytometry. Control cells were either pretreated with 10 
 
 
 
M
cytochalasin D for 0.5 h before adding Bodipy–
 
E.
 
 coli.
Bactericidal Activity.  LCD25 bacteria, labeled with 3H-argi-
nine as described in a previous paragraph (Bacterial Protein Degra-
dation), were added to XS52 cells in XS medium without antibi-
otics. Bacteria were added at a cell/bacteria ratio of 1:50. After
incubation at 37 C for 0.5 h, the cells were washed and incubated
for 0.5 or 2 h in XS medium without antibiotics. Cells and media
were harvested together and cells were lysed by adding Triton
X-100 (final concentration   0.2%). Samples were serially di-
luted in PBS, and 100  l of several dilutions were spread on LB
agar plates. After overnight incubation at 37 C, the colonies were
counted and the total number of CFUs recovered from each well
was calculated. The total number of bacteria associated with cells
after the wash was determined by measuring the cell-associated
3H dpm at this time and dividing by the 3H dpm/CFU.
mRNA Analysis.  Total RNA was isolated from untreated
or treated XS52 cells (RNAqueous Kit; Ambion). A region of
the AOAH cDNA was amplified using primers Seq_mAOAH-
ex12F (5 - CCAACTCTCTGGTGTAACTGGATTT-3 ) and
Seq_mAOAH-ex12R (5 -TCTCAAACGATGGTAAATGGA-
TTTT-3 ). The probe (TaqMan® MGB, FAM™ dye-labeled)
5 -ACGAGTGGAATTGAAG-3  and primers were designed
and synthesized by Applied Biosystems. Plasmid PMF612, which
contains murine AOAH cDNA, was used as a reference
molecule for the standard curve calculation. TaqMan® rodent
GAPDH control reagents were used to measure GAPDH gene
expression. All real-time PCR reactions were performed in a
25- l mixture with TaqMan® one-step RT-PCR Master Mix
Reagents Kit on a sequence detection system (model ABI
PRISM® 7700).
Results
Immature (XS52) DCs and BMDCs Express AOAH.
We first measured LPS-deacylating activity in lysates of
XS52 cells, immature BMDCs, a mature DC line, XS106,
and several murine macrophage lines. Both XS52 cells and
BMDCs had LPS-deacylating activity similar to that of mu-
rine peritoneal macrophages and greater than that of the
other cell lines tested (Fig. 1 B). Mature DCs (XS106) ex-
pressed much lower activity than immature DCs (XS52).
XS52 Cells and BMDCs Deacylate the LPS in Whole Bacte-
ria in an AOAH-like Manner.  In the assay described in the
previous paragraph, we used purified LPS as the substrate
and measured its deacylation by cell lysates in the presence
of detergent. Next, we studied the ability of DCs to deacyl-
ate LPS in its natural setting, the outer membrane of gram-
negative bacteria. Because the fatty acids cleaved from LPS,
and other bacterial lipids can be degraded by host cells and/T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
1748 Dendritic Cells Deacylate Bacterial Lipopolysaccharide
or incorporated into cellular lipids, we measured the disap-
pearance of individual fatty acids from the LPS backbone.
We found that both XS52 cells and BMDCs deacylated the
LPS in whole bacteria in an AOAH-like manner (Fig. 2, A
and B). 3-OH-14:0, the primary fatty acyl chain of lipid A,
was not removed from the LPS backbone, whereas the
nonhydroxylated (secondary) fatty acids (12:0 and 14:0)
were cleaved over time. Confirmation that AOAH is the
deacylating enzyme came from a comparison of BMDCs
from AOAH wild-type ( / ) and AOAH null ( / ) 129
mice. BMDCs from AOAH /  mice deacylated signifi-
cantly less LPS than their wild-type counterparts (Fig. 2, B
and C); the apparent removal of 20–30% of the 12:0 by
AOAH /  BMDCs /  is unexplained because they were
unable to deacylate purified LPS (unpublished data), and
peritoneal macrophages from AOAH /  mice did not
deacylate the LPS in E. coli (Fig. 2, D and E).
Regulation of AOAH Activity in XS52 Cells.  In vitro,
DCs can be induced to mature by inflammatory cytokines,
by CD40 ligand, or by microbes or microbial molecules
such as LPS and peptidoglycan. Following the protocol of
Yamada and Katz (17), we treated XS52 cells with 10 ng/
ml IL-4 for 6 d and for an additional 3 d with a maturation
cocktail that included IL-4, TNF , IL-1 , and an agonistic
CD40 antibody. To assess the maturation state of the cells,
we measured cell surface markers by using flow cytometry.
Increased surface expression of CD40, a costimulatory
molecule, was used to reflect maturation (17). The LPS
binding receptor, CD14, which is constitutively expressed
on the XS52 cell surface, was shown to be down-regulated
on XS52 cells treated with IL-4 and maturation cocktail.
We also measured the phagocytic activity of untreated and
treated cells. Immature DCs, which are highly phagocytic,
lose this capability when they mature (5, 23).
After treatment with IL-4 for 6 d and the cytokine cock-
tail for three more days, CD40 expression on XS52 cells
had increased a little (Fig. 3 A), whereas CD14 expression
(Fig. 3 A) and phagocytic activity (Fig. 3 B) had decreased.
These changes were accompanied by a sixfold decrease in
AOAH activity (Fig. 3 C).
In the same experiments, we asked if exposing the cells to
LPS or gram-negative bacteria would alter their ability to
phagocytose or to express AOAH. After XS52 cells had
been incubated with LPS or whole gram-negative bacteria
for 9 d, their surface expression of CD40 increased, whereas
CD14 expression, phagocytic activity, and AOAH activity
were maintained or slightly increased (Fig. 3, A–C).
Prolonged incubation in the presence of LPS or E. coli
was associated with some loss of XS52 cell viability. When
Figure 1. LPS deacylation by cell lysates. (A) Structure of the lipid A
moiety of E. coli LPS. AOAH (arrows) cleaves the secondary fatty acyl
chains (laurate, 12:0; myristate, 14:0) attached in ester (acyloxyacyl) link-
age to the glucosamine-linked 3-hydroxymyristoyl residues. (B) LPS
deacylation by cell lysates. Lysates of cultured cells were assayed for their
ability to deacylate purified 3H/14C-LPS as described in Materials and
Methods. Each bar shows the mean of three or more independent exper-
iments. Error bars represent 1 SEM. Asterisks, significantly different from
XS52 cells: **, P   0.01; ***, P   0.001 (Student’s t test).
Figure 2. Deacylation of LPS in E. coli. (A) Deacylation of LPS in E.
coli by XS52 cells. (B and C) Deacylation of LPS in E. coli by BMDCs
from AOAH /  (B) and AOAH /  (C) mice. (D and E) Deacylation of
LPS in E. coli by thioglycollate-elicited peritoneal macrophages from
AOAH /  (D) and AOAH /  (E) mice. The data in each panel are rep-
resentative of two or more experiments with similar results. FA, fatty acid.T
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we treated XS52 with LPS or E. coli for 24 h, with no loss
of cell numbers, the results were similar: maintenance of
CD14 expression, phagocytic ability, and AOAH activity
were accompanied by increased expression of CD40 (un-
published data).
To investigate the basis for the changes in AOAH activ-
ity, we measured AOAH mRNA abundance in XS52 cells
using real-time PCR. As shown in Fig. 3 D, AOAH
mRNA abundance decreased eightfold after treatment with
the maturation cocktail and increased twofold after treat-
ment with LPS.
Maturation of XS52 cells, when induced by proinflam-
matory cytokines and an agonistic CD40 antibody, was thus
associated with decreases in CD14 expression, phagocytic
activity, and AOAH activity, whereas CD40 expression was
enhanced. Although treatment with LPS or gram-negative
bacteria was also followed by increased expression of the co-
stimulatory molecule, CD40, the cells maintained their abil-
ity to recognize LPS, internalize bacteria, and deacylate LPS.
Regulation of AOAH Activity in BMDCs.  We treated
BMDCs with IL-4 and the same maturation cocktail for
2 d. CD40 and CD86 expression increased (Fig. 4 A),
whereas phagocytic activity decreased (Fig. 4 B). Immature
BMDCs expressed very little CD14, and treatment with
maturation cocktail did not change its expression (unpub-
lished data). Cytokine-induced maturation decreased
AOAH activity by sixfold (Fig. 4 C).
When BMDCs were treated with 10 ng/ml LPS for 2 d,
they expressed more surface CD40 and CD86 (Fig. 4 A)
and slightly more CD14 (reference 24; unpublished data),
whereas their phagocytic activity decreased (Fig. 4 B).
AOAH activity increased by threefold (Fig. 4 C). Up-regu-
lation of costimulatory molecules has also been described
previously in Salmonella-infected BMDCs in vitro (25) and
in response to LPS in vivo (26). Thus, the maturation
cocktail and LPS both augment cell surface CD40 and
CD86 expression in BMDCs and decrease their phagocytic
activity. The maturation cocktail decreases BMDC AOAH
activity whereas LPS increases it.
Other Bacterial Agonists Also Increase AOAH Expression in
BMDCs.  Next, we wanted to know if the augmentation
of AOAH activity is LPS-specific because LPS is an AOAH
Figure 3. Stimulus-induced changes in XS52 cells. (A) Cell surface ex-
pression of CD14 and CD40 on untreated XS52 cells and on cells treated
with cytokines (IL-4 and maturation cocktail), 10 ng/ml LPS, or 105
CFU/ml E. coli for 9 d (Materials and Methods). Black line, specific anti-
body; gray line, control antibody of the same isotype. (B) Flow cytomet-
ric analysis of phagocytosis of Bodipy-labeled E. coli. Dotted line, cells
only; black line, cells with Bodipy–E. coli; gray line, after pretreatment
with cytochalasin D to inhibit phagocytosis. (C) LPS-deacylating activity
in cell lysates. Each experimental condition was assayed in duplicate; the
results are combined from nine independent experiments. (D) AOAH
mRNA abundance as assessed by real-time PCR measurements of
AOAH and GAPDH mRNA. The data are combined from two inde-
pendent experiments. (C and D) Bars represent means  1 SD.T
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substrate. LPS is thought to activate DCs by interacting
with the toll-like receptor (TLR) 4–MD-2 signaling com-
plex. To find out if cell activation via other TLRs can in-
crease or decrease AOAH expression, we incubated BM-
DCs with bacterial CpGs (TLR9 agonist; references 27,
28) and M. luteus (gram-positive bacterium; agonist for
TLR2 [29], possibly also other TLRs). When we tested the
working suspension of each preparation using Limulus
amebocyte lysate (Cape Cod Inc.), the endotoxin levels
were  0.03 EU/ml. As shown in Fig. 4 C, CpG and M.
luteus both increased AOAH activity whereas GpC did not.
These results indicate that BMDC AOAH can be regulated
via signals downstream of TLRs other than TLR4.
After Exposure to Maturation Cocktail or LPS, XS52 Cells
Alter Their Ability to Deacylate LPS in Whole Bacteria.  We
explored how different stimuli affect the ability of XS52
cells to deacylate the LPS in whole bacteria. XS52 cells
treated with IL-4 for 6 d and maturation cocktail for three
additional days were compared with XS52 cells treated
with LPS and with control cells that had been maintained
without stimulation. The ability of the cells to deacylate
LPS in E. coli was abolished in the maturation cocktail–
treated group (Fig. 5 B) and was increased by LPS treat-
ment (Fig. 5 C). In parallel experiments, we studied the
ability of the cells to degrade bacterial protein. Protein
degradation was fourfold lower in maturation cocktail–
treated XS52 cells than in untreated cells, whereas LPS
treatment maintained the protein degradation rate (Fig. 5
D). Under the conditions studied here, maturation thus al-
tered the cells’ ability to degrade bacterial LPS and protein
in a similar fashion.
Differentiation Also Influences the Bactericidal Activity of DCs.
IL-4– and maturation cocktail–treated XS52 cells were less
able (by 50%) to kill E. coli, whereas LPS treatment main-
tained or slightly increased killing (Fig. 6).
Discussion
Deacylation of the lipid A moiety of LPS was first de-
scribed (30) in Dictyostelium discoideum, a slime mold that
digests internalized bacteria as a foodstuff. The discovery
that human neutrophils can also carry out LPS deacylation
was reported in 1983 (19), and subsequent work identified
an LPS-deacylating enzyme, AOAH, in myeloid lineage
cells from numerous animals. Mouse, rabbit, and human
enzymes have over 70% amino acid sequence identity/sim-
ilarity (31), whereas D. discoideum and mouse AOAH genes
encode proteins that have  30% overall amino acid se-
quence similarity, with identity in four of the five sequence
motifs that place the enzyme in the GDSL lipase family
(reference 32; unpublished data). Although the enzyme has
thus been highly conserved during evolution, the role(s)
that it plays in modulating immune responses to LPS are
not well understood.
The results of the present experiments provide strong
evidence that AOAH is the major, if not the only, mam-
malian enzyme that deacylates the LPS contained in phago-
cytosed bacteria. We also identified a previously unsus-
pected role in LPS deacylation for DCs, key cells in the
innate immune response to invading bacteria.
We first found that lysates of immature DCs, whether
derived from skin (XS52 cells) or bone marrow, had
Figure 4. Maturation-induced
changes in BMDCs. (A) Cell
surface expression of CD40 and
CD86 on BMDCs and on
BMDCs treated with maturation
cocktail (see Materials and Meth-
ods), 10 ng/ml LPS, 1  M CpG
ODN, 1  M GpC ODN, and
40   g/ml  M. luteus for 2 d.
Black line, specific antibody;
shaded gray histogram, control
antibody of the same isotype. (B)
Phagocytosis of Bodipy-labeled
E. coli. Dotted line, cells only;
black line, cells with Bodipy–
E. coli; gray line, after pretreat-
ment with cytochalasin D to
inhibit phagocytosis. (C) LPS-
deacylating activity in cell ly-
sates. Each experimental condi-
tion was assayed in duplicate; the
results are combined from two
or more independent experi-
ments. (C) Bars show the mean
 1 SE.T
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AOAH activity that was equivalent to the activity found in
peritoneal macrophages and considerably greater than that
in several macrophage cell lines. Second, both XS52 cells
and BMDCs deacylated, in an AOAH-like manner, the
LPS contained in the E. coli that they ingested; this ability
was greatly diminished in BMDC and macrophages from
AOAH-deficient mice, indicating that this enzyme is
largely, if not entirely, responsible for LPS deacylation in
these cells. The absence of enzymes that remove any of the
four glucosamine-linked hydroxylated fatty acids from LPS
suggests that animals may have other mechanisms for di-
gesting, and/or disposing of, partially deacylated LPS (33).
The high levels of AOAH activity found in immature
DCs and in macrophages raise the possibility that these cells
play important roles in regulating the body’s responses to
bioactive LPS. In this regard, it is intriguing that AOAH-
deficient mice have exaggerated antibody responses to LPS
(unpublished results); because the ability of extracellular
AOAH to deacylate LPS is quite limited (34) and B cells do
not produce the enzyme, partial deacylation of LPS by
phagocytes may be required to limit B cell responses to
gram-negative bacterial LPS in vivo.
The third significant finding from these experiments is
that DCs can regulate their ability to deacylate LPS ac-
cording to external cues. In response to a mixture of in-
flammatory cytokines and an agonistic CD40 antibody,
DCs down-regulated their AOAH activity, whereas LPS
treatment increased it. The enzymatic activity measured in
cell lysates changed in concert with the ability of the cells
to deacylate the LPS in phagocytosed bacteria. The regu-
lation of AOAH expression was due, at least in part, to
differential expression or degradation of AOAH mRNA.
The finding that LPS treatment can increase AOAH
mRNA abundance in murine macrophages (10–20-fold)
and in vivo in mouse lung and liver (3–6-fold) was de-
scribed by Cody et al. (35); whereas none of the stimuli
used in their paper decreased AOAH mRNA or enzy-
matic activity in macrophages, we found that treatment
with IL-4 and maturation cocktail greatly reduced AOAH
in DCs. Thus, it appears that both up- and down-regula-
tion of this low abundance enzyme can occur in phago-
cytes. The results of microarray analyses of AOAH
mRNA abundance in human peripheral blood leukocytes
(36) support this conclusion.
Fourth, we found that both XS52 cells and BMDCs also
regulate their ability to internalize and kill E. coli. Although
XS52 cells responded to IL-4 and maturation cocktail
treatment by diminishing their ability to phagocytose, kill,
and digest E. coli, exposure to either E. coli or to LPS main-
tained the cells’ phagocytic ability, CD14 expression,
AOAH activity, and the ability to kill and digest internal-
ized bacteria. Expression of a costimulatory molecule
(CD40), used here as a marker of maturation, increased
slightly during the response to all of the stimuli studied.
Figure 5. Impact of exogenous stimuli on the deacylation of LPS and
degradation of bacterial protein in phagocytosed E. coli. (A–C) XS52
cells, untreated or treated for 9 d with IL-4 and maturation cocktail or
LPS (Materials and Methods), were allowed to take up 14C-labeled E. coli
for 1 h. After washing to remove unattached cells and further incubation
for 6 h, 30% of the 12:0 and 14:0 had been removed from the LPS back-
bone in untreated cells (A), whereas 60–70% was removed in LPS-treated
cells (C, P   0.05, Student’s t test). Cytokine treatment abolished the
ability of the cells to deacylate the LPS in E. coli (B). (D) XS52 cells, un-
treated or treated with IL-4 and maturation cocktail or LPS, were incu-
bated with 3H-arginine–labeled  E. coli for 1 h. IL-4 and maturation
cocktail treatment decreased protein degradation whereas LPS treatment
maintained it. Treatment with IL-4 and maturation cocktail also reduced
phagocytosis (see Fig. 3 B); this likely contributed to the decrease in LPS
deacylation and protein degradation seen in these cells. The data shown in
each panel are from one of three experiments with similar results. Error
bars indicate   1 SD.
Figure 6. Impact of cell matu-
ration on bactericidal activity
Treatment for 9 d with IL-4 and
maturation cocktail treatment
decreased XS52 cells’ ability to
kill  E. coli by  50% (*, P  
0.05, Student’s t test), whereas
LPS maintained bactericidal ac-
tivity or increased it by  20%
(#, P    0.1). Data shown are
mean   1 SD from three inde-
pendent experiments.T
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These results are consistent with the currently accepted
paradigm in which immature DCs can internalize and pro-
cess bacterial antigens (37), whereas mature DCs lose these
capabilities as they gain in antigen-presenting ability (2, 4,
38). Together with the results of others (39–41), our find-
ings suggest that immature DCs contribute not only to the
processing of bacterial antigens but also to the host’s innate
armamentarium for killing invading bacteria and disabling
their stimulatory molecules.
When BMDCs were treated with LPS, in contrast, their
phagocytic activity decreased as AOAH activity increased.
This finding suggests that phagocytosis (as well as endocy-
tosis [42]) and AOAH expression may be regulated inde-
pendently in BMDCs. Differential regulation downstream
of the LPS signal has also been suggested by the reduced
ability of LPS to induce cytokines in MyD88-deficient
DCs whereas LPS induction of costimulatory molecule ex-
pression was intact (43, 44). Similarly, inhibition of p38
SAPK prevented LPS-induced up-regulation of CD80,
CD83, and CD86 in monocyte-derived DCs, but did not
affect changes in macropinocytosis or HLA-DR and CD40
expression (45). Furthermore, Rescigno et al. (46) found
that LPS induced NF- B translocation and that inhibition
of NF- B with a serine protease inhibitor prevents D1 (a
murine DC line) maturation (CD86 and class II expres-
sion), but does not interfere with the ability of LPS to pre-
vent DC apoptosis. In contrast, Sallusto et al. (47) found
that human monocyte-derived DCs respond to LPS as well
as TNF and IL-1 with a coordinated series of changes that
include down-regulation of macropinocytosis and Fc re-
ceptors, disappearance of the class II compartment, and up-
regulation of adhesion and costimulatory molecules.
Finally, it is noteworthy that AOAH activity increased
as DCs recognized microbial agonists that activate them
via several different TLRs. Thus, maintaining or increas-
ing the ability to deacylate LPS seems to be a DC response
to sensing diverse microbial molecules, including those in
a gram-positive bacterium (M. luteus), which does not
contain LPS. Expression of TLR4 is required for LPS, but
not gram-negative bacteria, to induce the maturation of
BMDCs (39).
In all phagocytes studied in vitro to date, LPS deacyla-
tion has occurred over many hours (21, 48). Thus, it is un-
likely that AOAH influences the ability of the phagocy-
tosing cell to respond to the LPS in a bacterial cell wall.
Because the long-term fate of LPS within phagocytes is un-
known, it is possible that LPS deacylation might either di-
minish a phagocyte’s late responses to LPS, or even reduce
the responses of other cells that encounter LPS (either on
the surface of the phagocyte (49, 50), or after the LPS has
been released into the phagocyte’s environment; reference
51). It is also intriguing that animals should deacylate LPS
so selectively: when AOAH acts on ingested E. coli, all of
the hydroxylated fatty acyl chains remain attached to the
glucosamine backbone of lipid A. Previous authors have
raised the possibility that the partially deacylated (thus,
tetra-acyl) LPS produced by AOAH could act as an LPS
antagonist in vivo (9, 10, 52). The discovery of stimulus-
regulated deacylation of LPS by DCs provides a new impe-
tus for investigating the biological significance of LPS deg-
radation by animals and the role(s) that DCs play in anti-
bacterial host defense.
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